Published in Medical Letter on the CDC and FDA, November 26th, 2006
Omnaris is an intranasal corticosteroid containing Ciclesonide as active substance. It is indicated for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in patients 12 years of age and older. In addition, the FDA determined Omnaris approvable for the indication in children ages 2 to 11 years of age.
"With the approval of Omnaris we offer patients with allergic rhinitis an innovative treatment option," said Hans-Joachim Lohrisch, member of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA